Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Lerebours

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
Breast Cancer Research : BCR|June 5, 2024
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog studyMylène Duivon, Justine Lequesne, Antonio Di Meglio, et al.
Plos One|December 20, 2015
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
Breast Cancer Research : BCR|September 15, 2020
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapyLuc Cabel, Dan Rosenblum, Florence Lerebours, et al.
The Lancet. Oncology|March 2, 2012
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 studyJean-Yves Pierga, Thierry Petit, Thierry Delozier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2014
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival dataJean-Yves Pierga, Thierry Petit, Christelle Lévy, et al.
Oncogene|February 27, 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysisAntoine Vasseur, Luc Cabel, Caroline Hego, et al.
Plos One|July 9, 2016
Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
Advances in Radiation Oncology|March 18, 2024
Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life ExperienceThais Tison, Pierre Loap, Emilie Arnaud, et al.
Cancers|July 9, 2022
No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NACBeatriz Grandal, Ashwaq Aljehani, Elise Dumas, et al.
Journal of Translational Medicine|October 28, 2024
Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapyFrançois Bertucci, Arnaud Guille, Florence Lerebours, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
Breast Cancer Research : BCR|June 5, 2024
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog studyMylène Duivon, Justine Lequesne, Antonio Di Meglio, et al.
Plos One|December 20, 2015
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
Breast Cancer Research : BCR|September 15, 2020
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapyLuc Cabel, Dan Rosenblum, Florence Lerebours, et al.
The Lancet. Oncology|March 2, 2012
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 studyJean-Yves Pierga, Thierry Petit, Thierry Delozier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2014
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival dataJean-Yves Pierga, Thierry Petit, Christelle Lévy, et al.
Oncogene|February 27, 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysisAntoine Vasseur, Luc Cabel, Caroline Hego, et al.
Plos One|July 9, 2016
Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
Advances in Radiation Oncology|March 18, 2024
Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life ExperienceThais Tison, Pierre Loap, Emilie Arnaud, et al.
Cancers|July 9, 2022
No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NACBeatriz Grandal, Ashwaq Aljehani, Elise Dumas, et al.
Journal of Translational Medicine|October 28, 2024
Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapyFrançois Bertucci, Arnaud Guille, Florence Lerebours, et al.
Pageof 10